- Design
- Systematic review and meta-analysis of 22 randomised trials
- Population
- 28,112 adults after elective total hip arthroplasty
- Primary outcome
- Venous thromboembolism and bleeding
- Effect
- VTE OR 0.62 (95% CI 0.47–0.82); bleeding OR 1.19 overall, 1.06 (0.95–1.18) for UK-licensed doses
This meta-analysis pooled 22 randomised trials with 28,112 patients comparing direct oral anticoagulants with low molecular weight heparin for thromboprophylaxis after elective total hip replacement.
Venous thromboembolism was less common with oral anticoagulants (OR 0.62), driven by fewer deep vein thromboses. Across all trials, bleeding was slightly more frequent (OR 1.19), but when the analysis was limited to drugs and doses licensed in the UK, bleeding did not differ (OR 1.06). Reoperation and mortality were similar.
Physicians are often asked to advise on prophylaxis for surgical patients, particularly those with renal impairment, frailty or other drugs on board. Tablets are also easier to continue after discharge than daily injections, which matters for adherence over a five-week course.
The trials span many years and several agents, some no longer used at the doses tested, and most outcomes were asymptomatic venographic clots. This is evidence for oral agents at licensed doses, not for higher doses. Indian orthopaedic practice varies widely here, and local protocols still apply.
- Consider a direct oral anticoagulant at licensed thromboprophylaxis doses after elective hip replacement when advising surgical colleagues.
- Check renal function, weight and interacting drugs before choosing the agent and dose.
- Confirm the planned duration of prophylaxis is written on the discharge prescription.
- Stay with heparin where oral intake, absorption or severe renal impairment make tablets unsuitable.
- Follow the hospital's orthopaedic protocol where it specifies an agent.
Why it matters
It settles a common referral question for physicians advising on surgical patients and makes discharge easier.
Don't overread it
Most clots counted were asymptomatic, and the bleeding reassurance rests on a subgroup of licensed doses.
The statistics, in plain English
An odds ratio of 0.62 means about 38% lower odds of a clot with oral agents. The overall bleeding odds ratio of 1.19 (1.03 to 1.38) is small but real; restricting to licensed doses gave 1.06 (0.95 to 1.18), an interval that includes no difference. A subgroup restricted by licence is a reasonable but post-hoc way to judge what applies today.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for internal medicine, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free